

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Hong Kong prospectus dated December 29, 2023 (the “**Prospectus**”) of Concord Healthcare Group Co., Ltd. (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States. The H Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

No stabilizing manager will be appointed, and it is anticipated that no stabilization activities will be carried out in relation to the Global Offering.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to terms and conditions set out in the Prospectus. Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date.



CONCORD HEALTHCARE GROUP CO., LTD.*
美中嘉和醫學技術發展集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 39,420,200 H Shares
Number of Hong Kong Offer Shares	: 3,942,200 H Shares (subject to reallocation)
Number of International Offer Shares	: 35,478,000 H Shares (subject to reallocation)
Maximum Offer Price	: HK\$16.40 per H Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	: RMB1.00 per H Share
Stock Code	: 2453


*Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers
(in alphabetical order)*



Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers



Joint Bookrunners and Joint Lead Managers



IMPORTANT NOTICE TO INVESTORS: FULLY ELECTRONIC APPLICATION PROCESS

We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of the Prospectus to the public in relation to the Hong Kong Public Offering.

The Prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “*HKEXnews > New Listings > New Listing Information*” section, and our website at www.concordmedical.com. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online through the **White Form eIPO** service at www.eipo.com.hk; or
- (2) apply through the **HKSCC EIPO channel** to electronically cause HKSCC Nominees to apply on your behalf by instructing your **broker** or **custodian** who is a HKSCC Participant to give **electronic application instructions** through HKSCC’s FINI system to apply for the Hong Kong Offer Shares on your behalf.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the prospectus are identical to the printed document as registered with the Registrar of Companies in Hong Kong pursuant to section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

If you are an **intermediary, broker or **agent**, please remind your customers, clients or principals, as applicable, that the prospectus is available online at the website addresses above.**

Please refer to the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details of the procedures through which you can apply for the Hong Kong Offer Shares electronically.

Your application through the **White Form eIPO** service at www.eipo.com.hk or **HKSCC EIPO channel** must be for a minimum of 200 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select.

No. of Hong Kong Offer Shares applied for	Amount payable on application ⁽²⁾ HK\$	No. of Hong Kong Offer Shares applied for	Amount payable on application ⁽²⁾ HK\$	No. of Hong Kong Offer Shares applied for	Amount payable on application ⁽²⁾ HK\$	No. of Hong Kong Offer Shares applied for	Amount payable on application ⁽²⁾ HK\$
200	3,313.08	3,000	49,696.18	40,000	662,615.75	500,000	8,282,697.00
400	6,626.16	4,000	66,261.58	50,000	828,269.70	600,000	9,939,236.40
600	9,939.24	5,000	82,826.96	60,000	993,923.65	700,000	11,595,775.80
800	13,252.31	6,000	99,392.37	70,000	1,159,577.58	800,000	13,252,315.20
1,000	16,565.39	7,000	115,957.76	80,000	1,325,231.52	900,000	14,908,854.60
1,200	19,878.47	8,000	132,523.15	90,000	1,490,885.45	1,000,000	16,565,394.00
1,400	23,191.55	9,000	149,088.55	100,000	1,656,539.40	1,200,000	19,878,472.80
1,600	26,504.63	10,000	165,653.95	200,000	3,313,078.80	1,400,000	23,191,551.60
1,800	29,817.71	20,000	331,307.88	300,000	4,969,618.20	1,600,000	26,504,630.40
2,000	33,130.79	30,000	496,961.82	400,000	6,626,157.60	1,971,000 ⁽¹⁾	32,650,391.58

(1) Maximum number of Hong Kong Offer Shares you may apply for.

(2) The amount payable is inclusive of brokerage, SFC transaction levy, Stock Exchange trading fee and AFRC transaction levy. If your application is successful, brokerage will be paid to the Exchange Participants (as defined in the Listing Rules) and SFC transaction levy, Stock Exchange trading fee and AFRC transaction levy are paid to the Stock Exchange (in the case of SFC transaction levy and in the case of AFRC transaction levy, collected by the Stock Exchange on behalf of the SFC and the AFRC respectively).

No application for any other number of the Hong Kong Offer Shares will be considered and any such application is liable to be rejected.

APPLICATION FOR LISTING ON THE STOCK EXCHANGE

We have applied to the Stock Exchange for the grant of listing of, and permission to deal in, the H Shares to be issued pursuant to the Global Offering and the 207,130,824 H Shares to be converted from Domestic Shares. Dealings in the H Shares on the Stock Exchange are expected to commence on Tuesday, January 9, 2024.

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 3,942,200 H Shares (subject to reallocation) in Hong Kong, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering, and
- the International Offering of initially 35,478,000 H Shares (subject to reallocation), representing approximately 90% of the total number of Offer Shares initially available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 to the Listing Rules and Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, the Overall Coordinators (for themselves and on behalf of the other Underwriters) may, at their sole discretion, reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to the reallocation mechanism as described in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus, the maximum total number of Offer Shares that may be allocated to the Hong Kong Public Offering following such reallocation shall be 7,884,200 Offer Shares, representing approximately twice the number of the Offer Shares initially available under the Hong Kong Public Offering and approximately 20% of the number of the Offer Shares initially available under the Global Offering and the Offer Price shall be fixed at HK\$14.10 per Offer Share (being the low-end of the indicative Offer Price range).

PRICING

The Offer Price will be no more than HK\$16.40 per Offer Share and is expected to be no less than HK\$14.10 per Offer Share unless to be otherwise announced. Applicants for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$16.40 per Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%, amounting to a total of HK\$3,313.08 for one board lot of 200 H Shares, subject to refund if the Offer Price as finally determined is less than HK\$16.40 per Offer Share.

EXPECTED TIMETABLE

Hong Kong Public Offering commences	9:00 a.m. on Friday, December 29, 2023
Latest time to complete electronic applications under White Form eIPO service through the designated website at www.eipo.com.hk	11:30 a.m. on Thursday, January 4, 2024
Application lists of the Hong Kong Public Offering open	11:45 a.m. on Thursday, January 4, 2024
Latest time for (a) completing payment of White Form eIPO applications by effecting internet banking transfer(s) or PPS payment transfer(s) and (b) giving electronic application instructions to HKSCC	12:00 noon on Thursday, January 4, 2024
If you are instructing your broker or custodian who is a HKSCC Participant to give electronic application instructions through HKSCC's FINI system to apply for the Hong Kong Offer Shares on your behalf, you are advised to contact your broker or custodian for the latest time for giving such instructions which may be different from the latest time as stated above.	
Application lists of the Hong Kong Public Offering close	12:00 noon on Thursday, January 4, 2024
Expected Price Determination Date	at or before 12:00 noon Friday, January 5, 2024
Announcement of:	
<ul style="list-style-type: none">• the final Offer Price;• the level of indications of interest in the International Offering;• the level of applications in the Hong Kong Public Offering; and• the basis of allocation of the Hong Kong Offer Shares	
to be published on the website of our Company at www.concordmedical.com and the website of the Stock Exchange at www.hkexnews.hk before	11:00 p.m. on Monday, January 8, 2024

Results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be available through a variety of channels, including:

- in the announcement to be posted on the website of our Company at www.concordmedical.com and the website of the Stock Exchange at www.hkexnews.hk, respectively Monday, January 8, 2024
- from the designated results of allocations website at www.iporeresults.com.hk (alternatively: www.eipo.com.hk/eIPOAllotment) with a "search by ID" function from 11:00 p.m. on Monday, January 8, 2024 to 12:00 midnight on Sunday, January 14, 2024
- from the allocation results telephone enquiry by calling +852 28628555 between 9:00 a.m. and 6:00 p.m. on Tuesday, January 9, 2024
Wednesday, January 10, 2024,
Thursday, January 11, 2024 and
Friday, January 12, 2024

H Share certificates in respect of wholly or partially successful applications to be dispatched or deposited into CCASS on or before Monday, January 8, 2024

e-Refund payment instructions/refund checks in respect of wholly or partially successful applications if the final Offer Price is less than the maximum Offer Price per Offer Share initially paid on application (if applicable) or wholly or partially unsuccessful applications to be dispatched/collected on or before Tuesday, January 9, 2024

Dealings in the H Shares on the Stock Exchange expected to commence at 9:00 a.m. on Tuesday, January 9, 2024

Note: Unless otherwise stated, all times and dates refer to Hong Kong local times and dates.

ELECTRONIC APPLICATION CHANNELS

The Hong Kong Public Offering period will begin at 9:00 a.m. on Friday, December 29, 2023 and end at 12:00 noon on Thursday, January 4, 2024 (Hong Kong time).

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

Application Channel	Platform	Target Investors	Application Time
White Form eIPO service	www.eipo.com.hk	Applicants who would like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name.	From 9:00 a.m. on Friday, December 29, 2023 to 11:30 a.m. on Thursday, January 4, 2024, Hong Kong time The latest time for completing full payment of application monies will be 12:00 noon on Thursday, January 4, 2024, Hong Kong time.
HKSCC EIPO channel	Your broker or custodian who is a HKSCC Participant will submit an EIPO application on your behalf through HKSCC's FINI system in accordance with your instruction.	Applicants who would not like to receive a physical Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account.	Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian.

The **White Form eIPO** service and the **HKSCC EIPO** channel are facilities subject to capacity limitations and potential service interruptions and you are advised not to wait until the last day of the application period to apply for Hong Kong Offer Shares.

For those applying through the **White Form eIPO** service, the application monies (including brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee) will be held by the receiving bank on behalf of the Company and the refund monies, if any, will be returned to you without interest on Tuesday, January 9, 2024.

For those applying through the **HKSCC EIPO** channel, your broker or custodian will arrange the refund monies, if any, to your designated bank account subject to the arrangement application monies paid between you and it.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus and the designated website (www.eipo.com.hk) for White Form eIPO service.

PUBLICATION OF RESULTS

The Company expects to announce the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on the Company’s website at www.concordmedical.com, and the website of the Stock Exchange at www.hkexnews.hk by 11:00 p.m. on Monday, January 8, 2024 (Hong Kong time).

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants (where applicable) under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares — B. Publication of Results” in the Prospectus.

SETTLEMENT

If an application is rejected, not accepted or accepted in part only, or if the Offer Price as finally determined is less than the maximum offer price of HK\$16.40 per Offer Share (excluding brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee thereon), or if the conditions of the Global Offering are not fulfilled in accordance with “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, AFRC transaction levy and Stock Exchange trading fee, will be refunded, without interest or the cheque or banker’s cashier order will not be cleared.

Subject to the granting of the approval for the listing of, and permission to deal in, the H Shares on the Stock Exchange and our compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Stock Exchange or any other date as determined by HKSCC. Settlement of transactions between Exchange Participants (as defined in the Hong Kong Listing Rules) is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made for the H Shares to be admitted into CCASS.

Investors should seek the advice of their stockbroker or other professional advisers for the details of the settlement arrangements as such arrangements may affect their rights and interests.

The Company will not issue temporary document of title in respect of the Offer Shares. The Company will not issue receipt for sums paid on application. H Share certificates will only become valid at 8:00 a.m. on Tuesday, January 9, 2024 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting” in the Prospectus has not been exercised. Investors who trade H Shares prior to the receipt of the H Share certificates or prior to the H Share certificates becoming valid do so entirely at their own risk.

COMMENCEMENT OF DEALINGS

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. in Hong Kong time on Tuesday, January 9, 2024, it is expected that dealings in the Company’s H Shares on the Stock Exchange will commence at 9:00 a.m. (Hong Kong time) on Tuesday, January 9, 2024. The H Shares will be traded in board lots of 200 H Shares each. The stock code of the Company’s H Shares will be 2453.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu

Chairman of the Board and Executive Director

Hong Kong, December 29, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. YANG Jianyu as chairman and executive Director, Ms. FU Xiao, Mr. CHANG Liang and Mr. SHI Botao as executive Directors, Mr. WANG Lei and Mr. CHEN Hongzhang as non-executive Directors, and Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.

* *For identification purposes only*